Literature DB >> 26123893

Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland's experience.

Sharon J Hutchinson1, John F Dillon2, Ray Fox3, Scott A McDonald4, Hamish A Innes4, Amanda Weir4, Allan McLeod5, Esther J Aspinall4, Norah E Palmateer5, Avril Taylor6, Alison Munro6, Heather Valerio4, Gareth Brown7, David J Goldberg4.   

Abstract

Seven years have elapsed since the Scottish Government launched its Hepatitis C Action Plan - a Plan to improve services to prevent transmission of infection, particularly among people who inject drugs (PWID), identify those infected and ensure those infected receive optimal treatment. The Plan was underpinned by industrial scale funding (around £100 million, in addition to the general NHS funding, will have been invested by 2015), and a web of accountable national and local multi-disciplinary multi-agency networks responsible for the planning, development and delivery of services. Initiatives ranged from the introduction of testing in specialist drug services through finger-prick blood sampling by non-clinical staff, to the setting of government targets to ensure rapid scale-up of antiviral therapy. The Plan was informed by comprehensive national monitoring systems, indicating the extent of the problem not just in terms of numbers infected, diagnosed and treated but also the more penetrative data on the number advancing to end-stage liver disease and death, and also through compelling modelling work demonstrating the potential beneficial impact of scaling-up therapy and the mounting cost of not acting. Achievements include around 50% increase in the proportion of the infected population diagnosed (38% to 55%); a sustained near two-and-a-half fold increase in the annual number of people initiated onto therapy (470 to 1050) with more pronounced increases among PWID (300 to 840) and prisoners (20 to 140); and reversing of an upward trend in the overall number of people living with chronic infection. The Action Plan has demonstrated that a Government-backed, coordinated and invested approach can transform services and rapidly improve the lives of thousands. Cited as "an impressive example of a national strategy" by the Global Commission on Drug Policy, the Scottish Plan has also provided fundamental insights of international relevance into the management of HCV among PWID.
Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HCV; PWID; Public health policy

Mesh:

Year:  2015        PMID: 26123893     DOI: 10.1016/j.drugpo.2015.05.019

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  10 in total

1.  Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.

Authors:  Hannah Fraser; Christinah Mukandavire; Natasha K Martin; David Goldberg; Norah Palmateer; Alison Munro; Avril Taylor; Matthew Hickman; Sharon Hutchinson; Peter Vickerman
Journal:  Addiction       Date:  2018-07-10       Impact factor: 6.526

2.  Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection.

Authors:  Eshan U Patel; Andrea L Cox; Shruti H Mehta; Denali Boon; Caroline E Mullis; Jacquie Astemborski; William O Osburn; Jeffrey Quinn; Andrew D Redd; Gregory D Kirk; David L Thomas; Thomas C Quinn; Oliver Laeyendecker
Journal:  J Infect Dis       Date:  2016-01-14       Impact factor: 5.226

Review 3.  The Elimination of Hepatitis C as a Public Health Threat.

Authors:  Margaret Hellard; Sophia E Schroeder; Alisa Pedrana; Joseph Doyle; Campbell Aitken
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

4.  Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.

Authors:  Benjamin Hudson; Alex J Walker; William L Irving
Journal:  J Med Virol       Date:  2017-08-30       Impact factor: 2.327

5.  'It's been a long haul, a big haul, but we've made it': hepatitis C virus treatment in post-transplant patients with virus recurrence: An interpretative phenomenological analysis.

Authors:  Anna Krzeczkowska; Paul Flowers; Zoe Chouliara; Peter Hayes; Adele Dickson
Journal:  Health Psychol Open       Date:  2018-08-06

6.  Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).

Authors:  Matthew Hickman; John F Dillon; Lawrie Elliott; Daniela De Angelis; Peter Vickerman; Graham Foster; Peter Donnan; Ann Eriksen; Paul Flowers; David Goldberg; William Hollingworth; Samreen Ijaz; David Liddell; Sema Mandal; Natasha Martin; Lewis J Z Beer; Kate Drysdale; Hannah Fraser; Rachel Glass; Lesley Graham; Rory N Gunson; Emma Hamilton; Helen Harris; Magdalena Harris; Ross Harris; Ellen Heinsbroek; Vivian Hope; Jeremy Horwood; Sarah Karen Inglis; Hamish Innes; Athene Lane; Jade Meadows; Andrew McAuley; Chris Metcalfe; Stephanie Migchelsen; Alex Murray; Gareth Myring; Norah E Palmateer; Anne Presanis; Andrew Radley; Mary Ramsay; Pantelis Samartsidis; Ruth Simmons; Katy Sinka; Gabriele Vojt; Zoe Ward; David Whiteley; Alan Yeung; Sharon J Hutchinson
Journal:  BMJ Open       Date:  2019-09-24       Impact factor: 2.692

Review 7.  Innovative strategies for the elimination of viral hepatitis at a national level: A country case series.

Authors:  Sophia E Schröeder; Alisa Pedrana; Nick Scott; David Wilson; Christian Kuschel; Lisa Aufegger; Rifat Atun; Ricardo Baptista-Leite; Maia Butsashvili; Manal El-Sayed; Aneley Getahun; Saeed Hamid; Radi Hammad; Ellen 't Hoen; Sharon J Hutchinson; Jeffrey V Lazarus; Olufunmilayo Lesi; Wangsheng Li; Rosmawati Binti Mohamed; Sigurdur Olafsson; Raquel Peck; Annette H Sohn; Mark Sonderup; Catherine W Spearman; Tracy Swan; Mark Thursz; Tim Walker; Margaret Hellard; Jessica Howell
Journal:  Liver Int       Date:  2019-09-04       Impact factor: 5.828

8.  Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.

Authors:  Alan Yeung; Norah E Palmateer; John F Dillon; Scott A McDonald; Shanley Smith; Stephen Barclay; Peter C Hayes; Rory N Gunson; Kate Templeton; David J Goldberg; Matthew Hickman; Sharon J Hutchinson
Journal:  J Hepatol       Date:  2021-10-09       Impact factor: 25.083

9.  Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan.

Authors:  Selena M Sagan; Benoit Dupont; Jason Grebely; Mel Krajden; Sonya A MacParland; Jennifer F Raven; Sahar Saeed; Jordan J Feld; D Lorne Tyrrell; Joyce A Wilson
Journal:  Can J Gastroenterol Hepatol       Date:  2016-04-27

Review 10.  Urgent action to fight hepatitis C in people who inject drugs in Europe.

Authors:  John F Dillon; Jeffrey V Lazarus; Homie A Razavi
Journal:  Hepatol Med Policy       Date:  2016-06-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.